



Should durvalumab be initiated at this point?



Should PD-L1 levels generally be tested in patients with locally advanced NSCLC?



In general, do you believe durvalumab should be used as consolidation treatment after chemoradiation therapy for patients with locally advanced NSCLC and a PD-L1 TPS of $\leq 1\%$?

Yes

54%



No

23%



I don't know


23%




In general, do you believe durvalumab should be used as consolidation treatment after chemoradiation therapy for patients with locally advanced NSCLC with an EGFR or ALK mutation?




A 70-year-old former smoker is about to undergo chemoradiation therapy for Stage IIIB NSCLC. The patient has asked you to estimate the chances that he or she will experience disease progression within 18 months with no further treatment beyond chemoradiation therapy. How would you respond?




If the patient in the previous scenario received consolidation durvalumab, what would you estimate to be the absolute reduction in the risk that he or she will experience disease progression within 18 months compared to chemoradiation therapy alone?



Should durvalumab be recommended as consolidation treatment?



In general, should durvalumab be recommended as consolidation treatment for an older, frail patient who is unable to tolerate chemotherapy and receives only radiation therapy for unresectable Stage IIIB NSCLC?



In general, should durvalumab be recommended as consolidation treatment for a patient with locally advanced NSCLC who underwent surgical excision and chemoradiation therapy as initial treatment?

Yes

34%



No

42%




I don't know


24%




What should be done?



In addition to supportive medication, would you initiate corticosteroids?



Should durvalumab be initiated?



Outside of a protocol setting, should durvalumab generally be offered as consolidation treatment after chemoradiation therapy to a patient with locally advanced NSCLC and Crohn's disease that is well controlled on infliximab?

Yes

25%



No

42%



I don't know

33%



Outside of a protocol setting, should durvalumab generally be offered as consolidation treatment after chemoradiation therapy to a patient with locally advanced NSCLC who has undergone a kidney transplant?

Yes

12%



No

56%




I don't know

32%



What treatment strategy is optimal?



What treatment strategy is optimal?

